Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...

Prostate cancer is one of the top diagnoses for men with cancer, but early stages are tough to detect.

A new study has highlighted a significant knowledge gap among patients about repeat radiotherapy (reirradiation) as a treatment option for recurrent prostate cancer ...

A new podcast fronted by writer, comedian and broadcaster Jon Holmes is aiming to help men better understand their prostate cancer treatment options ...

Accumulating evidence of possible benefit warrants randomized trials, experts say ...

Key Points Interested in Candel Therapeutics, Inc.? Here are five stocks we like better. Candel Therapeutics said it remains on track to file a BLA by year-end for aglatimagene in localized prostate ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Noninvasive monitoring of low-grade prostate cancer with a urinary biomarker test could reduce the need for biopsies and serial imaging, according to a study ...

More studies are needed to see if a shorter, more intense course of radiation therapy would be as effective against prostate cancer. Findings presented at medical meetings should be considered ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha radiopharmaceuticals ...